- AboutOpenClose
- TeamOpenClose
- CareersOpenClose
- Investment FocusOpenClose
- Contract Services & Enabling TechnologiesOpenClose
- Biotech & MedtechOpenClose
- Antimicrobial ResistanceOpenClose
- FoundryOpenClose
- PortfolioOpenClose
- MediaOpenClose
The Kineticos AMR Accelerator Fund I Invests in Orthobond Kineticos Strategic Advisor Steve Favaloro will join Orthobond’s Board of Directors…
Kincell Bio Announces New Board Chairman Mark R. Bamforth to Accelerate Company’s Growth and Expansion May 21st 2024 – Kincell Bio,…
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials, Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowl…
neuro42, a Kineticos Portfolio Company, Receives FDA Clearance on Portable and Compact Brain MRI Scanner for Point of Care Imaging…
Kineticos and INCATE join forces in supporting AMR innovators December 6th 2023 – INCATE (the INCubator for Antibacterial Therapies in…
Kineticos Life Sciences Announces Successful Final Close of approximately $60 Million for Kineticos Disruptor Fund II RALEIGH, N.C. | November…
Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies RALEIGH, N.C., AND…
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK |…
IMPuLSE Intestinal Microbiota Product in Liver Cirrhosis and Encephalopathy GLASGOW, United Kingdom | March 28, 2023 – EnteroBiotix Limited (“EBX”),…